Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Hodgkin Disease 35Lymphoma 18Urinary Bladder Neoplasms 10Neoplasms 3Melanoma 3Leukemia 2HIV Infections 2Glioma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urothelial Carcinoma of the Bladder 1Urethral Neoplasms 1Ureteral Neoplasms 1Survival Without Progression 1Skin Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pathologic Complete Response 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma, Malignant 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Kidney Neoplasms 1Desmoid Tumors 1

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bladder Adenocarcinoma × Vinblastine × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡